These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Prevalence and significance of anti-HCV antibodies. Author: De Groote J. Journal: Acta Gastroenterol Belg; 1991; 54(3-4):248-56. PubMed ID: 1665270. Abstract: The actual ELISA test for anti-HCV defects an antibody to a non-structural part of the virus. It is present in 0.3 to 1.5% of the blood donors and in about 60% of patients with chronic non-A, non-B hepatitis. Seroconversion occurs 4 to 6 months after the beginning of the disease. The risk of a sporadic transmission is very low but unknown. An ALT elevation occurred only in 7% of the sexual partners of positive chronic liver patients but nobody seroconverted. Vertical, mother to infant, transmission is rare. In all risk groups for HCV infection such as drug abuse, multiple transfusion, haemodialysis, the presence of the antibody is increased between 15 to 80%. There is also evidence that HCV may be an oncogenic factor for hepatocellular carcinoma. It is present in 30 to 60% of the cases.[Abstract] [Full Text] [Related] [New Search]